Obsessive -compulsive disorder. F42-The essential feature is recurrent obsessional thoughts or compulsive acts.obsessional thoughts are ideas,images,or impuses that enter the patients mind again and again in stereotyped form.They are , almost invariably distressing and the patient ofte
Conditions
Interventions
Intervention 1: In the first intervention group: In addition to SSRIs, it is given ondansetron at an average dose of 8 mg per day for 2 weeks. Intervention 2: In the control group, with SSRIs, the pa
Treatment - Drugs
In the first intervention group: In addition to SSRIs, it is given ondansetron at an average dose of 8 mg per day for 2 weeks.
In the control group, with SSRIs, the patient will receive the same dose of placebo for 12 weeks as the original drug.
Sponsors
Vice chancellor for resaerch Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Aged 18 years and over. Despite received at least three months of adequate and tolerable SSRI drugs, the scores of obsessive-compulsive scores 16 and up. No pregnancy or breastfeeding in women. No psychiatric disorder such as Bipolar in the axis 1 of psychiatry. Lack of mental retardation in the axis 2 of psychiatry. Lack of alcohol intake 6 months before the study. Lack of psychotherapy during the study.
Exclusion criteria
Exclusion criteria: Acute and severe physical illness during the study. Non-follow-up for 4 weeks. Severe complications during treatment. Not using contraceptive methods in females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity obsessive compulsion. Timepoint: Before the start of trial and every four weeks. Method of measurement: Yale Brown Obsessive -Compulsion Scala. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sudden drug effect. Timepoint: Before the start of the trial ,the end of the first-two-fourth-sixth-eighth-twelfth weeks. Method of measurement: Interviwe and examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra sepehrmanesh MD
Kashan University of Medical Sciences
Outcome results
None listed